Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention in Germany
Novel pharmaceutical treatments reducing cardiovascular events in dyslipidaemia patients must demonstrate clinical efficacy and cost-effectiveness to promote long-term adoption by patients, physicians, and insurers.
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
August 2023
|
| In: |
Cardiovascular drugs and therapy
Year: 2023, Jahrgang: 37, Heft: 4, Pages: 683-694 |
| ISSN: | 1573-7241 |
| DOI: | 10.1007/s10557-021-07310-y |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s10557-021-07310-y Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s10557-021-07310-y |
| Verfasserangaben: | Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Thomas Michaeli |
| Zusammenfassung: | Novel pharmaceutical treatments reducing cardiovascular events in dyslipidaemia patients must demonstrate clinical efficacy and cost-effectiveness to promote long-term adoption by patients, physicians, and insurers. |
|---|---|
| Beschreibung: | Online veröffentlicht: 11. Januar 2022 Gesehen am 09.07.2024 |
| Beschreibung: | Online Resource |
| ISSN: | 1573-7241 |
| DOI: | 10.1007/s10557-021-07310-y |